QS Pharma, the contract development and manufacturing organization acquired by Quotient Clinical in February 2017, has received approval from the European Medicines Agency (EMA) to manufacture certain medicinal products for commercial use in Europe.
 
QS Pharma’s manufacturing facility in Boothwyn, PA, was inspected in February 2017 by the Dutch Health Care Inspectorate (IGZ) at the request of the EMA. The assessment focused on two NDA filed products, and the overall quality systems of QS Pharma. Following the successful outcome, and past approvals from the FDA and PDMA, QS Pharma is now approved to manufacture medicinal products for the U.S., Europe and Japan.
 
Nutan Gangrade, managing director, QS Pharma, said, “QS Pharma is dedicated to maintaining a robust quality system, underpinned by our excellent regulatory history. This approval by the EMA ensures we are able to support customers with interests in Europe, creating further growth opportunities for the business.”
 
Mark Egerton, chief executive officer, Quotient Clinical, said, “QS Pharma is becoming a major global player in the commercial manufacture of market products, with a focus on high potency manufacturing, and niche therapies and markets such as orphan drugs, for tablets, capsules and oral liquids. This latest inspection and approval adds further value to the business.”